Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of ...

View Sarepta Therapeutics, Inc. (SRPT) current and estimated P/E ratio data provided by Seeking Alpha.

Sarepta Therapeutics has turned to dealmaking to restock a drug pipeline analysts worried was growing thin, announcing Tuesday a deal with Arrowhead Pharmaceuticals that will give it four clinical ...

Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based drugs to treat rare diseases in the muscle, nervous system ...

Arrowhead Pharmaceuticals (ARWR) stock surges 21% in premarket after $825M licensing deal with Sarepta (SRPT) for rare ...

Sarepta Therapeutics (SRPT), the leader in precision genetic medicine for rare diseases announced an exclusive global licensing and collaboration agreement with Arrowhead (ARWR) Pharmaceuticals ...

Shares of Sarepta Therapeutics SRPT have soared 43% year to date, significantly outperforming the industry’s 6.9% decline. The stock has also underperformed the sector and the S&P 500 during the ...

Sarepta is pressing forward with a bold plan to file with the FDA for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy (DMD) in the next few months, with a view to ...

Rare disease specialist Sarepta Therapeutics has joined with Selecta Biosciences in a research pact to develop ways to allow its gene therapies to be re-dosed. Sarepta is developing gene ...

After Sarepta (SRPT) announced a global licensing and collaboration agreement with Arrowhead (ARWR) that adds four clinical-stage siRNA assets for rare genetic diseases, Leerink analyst Joseph ...

An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the gene therapy. In the third quarter, Sarepta reported revenue from ...

Debt Management: Sarepta Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.14. Analyst Ratings: Simplified Analysts are ...